This HTML5 document contains 136 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n17http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00035/identifier/wikipedia/
n7http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00035/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00035/identifier/kegg-compound/
n23http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00035/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00035/identifier/drugbank/
n8http://linked.opendata.cz/resource/drugbank/patent/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00035/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00035/identifier/chebi/
n24http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00035
rdf:type
n3:Drug
n3:description
Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions, allowing you to sleep through the night without awakening to urinate. It is also used to treat specific types of diabetes insipidus and conditions after head injury or pituitary surgery.
n3:dosage
n13:271B40FA-363D-11E5-9242-09173F13E4C5 n13:271B40FB-363D-11E5-9242-09173F13E4C5 n13:271B40F2-363D-11E5-9242-09173F13E4C5 n13:271B40F3-363D-11E5-9242-09173F13E4C5 n13:271B40F4-363D-11E5-9242-09173F13E4C5 n13:271B40F5-363D-11E5-9242-09173F13E4C5 n13:271B40F6-363D-11E5-9242-09173F13E4C5 n13:271B40F7-363D-11E5-9242-09173F13E4C5 n13:271B40F8-363D-11E5-9242-09173F13E4C5 n13:271B40F9-363D-11E5-9242-09173F13E4C5 n13:271B40FC-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11380629 # Sequence Information "Link":http://www.ecplaza.net/tradeleads/seller/5605163/desmopressin_acetate.html
n3:group
approved
n3:halfLife
Oral t<sub>1/2</sub>=1.5-2.5 hours. Intranasal t<sub>1/2</sub>=3.3-3.5 hours. IV t<sub>1/2</sub> is biphasic: initial t<sub>1/2</sub>=7.8 minutes, terminal t<sub>1/2</sub>=0.4-4 hours.
n3:indication
Oral formulations may be used to manage primary nocturnal enuresis in adults and vasopressin sensitive diabetes insipidus, and for control of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Intranasal and parenteral formulations may be used to manage spontaneous or trauma-induced bleeds (e.g. hemarthrosis, intramuscular hematoma, mucosal bleeding) in patients with hemophilia A or von Willebrand's disease Type I. May also be used parenterally to prevent or treat bleeding in patients with uremia.
n3:manufacturer
n4:271B40D5-363D-11E5-9242-09173F13E4C5 n4:271B40D2-363D-11E5-9242-09173F13E4C5 n4:271B40D3-363D-11E5-9242-09173F13E4C5 n4:271B40D0-363D-11E5-9242-09173F13E4C5 n4:271B40D1-363D-11E5-9242-09173F13E4C5 n4:271B40DA-363D-11E5-9242-09173F13E4C5 n4:271B40D8-363D-11E5-9242-09173F13E4C5 n4:271B40D9-363D-11E5-9242-09173F13E4C5 n4:271B40D6-363D-11E5-9242-09173F13E4C5 n4:271B40D7-363D-11E5-9242-09173F13E4C5 n4:271B40D4-363D-11E5-9242-09173F13E4C5
owl:sameAs
n23:DB00035 n28:DB00035
dcterms:title
Desmopressin
adms:identifier
n10:PA449237 n11:Desmopressin n12:4450 n18:55566-5020-1 n19:C06944 n20:D00291 n21:DB00035
n3:mechanismOfAction
Desmopressin emulates the actions of endogenous human ADH (refer to Pharmacology section above). Desmpressin is a structural analogue of ADH modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. Compared to natural ADH, desmopressin elicits a great antidiuretic response on weight basis.
n3:packager
n4:271B40C9-363D-11E5-9242-09173F13E4C5 n4:271B40C6-363D-11E5-9242-09173F13E4C5 n4:271B40C7-363D-11E5-9242-09173F13E4C5 n4:271B40CC-363D-11E5-9242-09173F13E4C5 n4:271B40CD-363D-11E5-9242-09173F13E4C5 n4:271B40CA-363D-11E5-9242-09173F13E4C5 n4:271B40CB-363D-11E5-9242-09173F13E4C5 n4:271B40CE-363D-11E5-9242-09173F13E4C5 n4:271B40CF-363D-11E5-9242-09173F13E4C5 n4:271B40BC-363D-11E5-9242-09173F13E4C5 n4:271B40BD-363D-11E5-9242-09173F13E4C5 n4:271B40C0-363D-11E5-9242-09173F13E4C5 n4:271B40C1-363D-11E5-9242-09173F13E4C5 n4:271B40BE-363D-11E5-9242-09173F13E4C5 n4:271B40BF-363D-11E5-9242-09173F13E4C5 n4:271B40C4-363D-11E5-9242-09173F13E4C5 n4:271B40C5-363D-11E5-9242-09173F13E4C5 n4:271B40C2-363D-11E5-9242-09173F13E4C5 n4:271B40C3-363D-11E5-9242-09173F13E4C5 n4:271B40C8-363D-11E5-9242-09173F13E4C5
n3:patent
n8:7022340 n8:2484724 n8:2486833 n8:5500413
n3:synonym
Desmopressinum 1-Desamino-8-D-arginine vasopressin Desmopressin DDAVP Minirin Desmopressine 1-deamino-8-D-arginine vasopressin Desmopresina Stimate 1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin
n3:toxicity
Overdose may lead to increased duration of action and lead to symptoms such as fluid retention, headaches, abdominal cramps, nausea, and facial flushing. Adverse effects include headache, nausea, abdominal pain, facial flushing, dizziness, dry mouth, and hyponatremia. Nasal congestion and rhinitis have been reported with nasal spray formulations.
n6:hasAHFSCode
n7:68-28-00
n3:proteinBinding
50%
n3:salt
n3:synthesisReference
Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, "High purity desmopressin produced in large single batches." U.S. Patent US5674850, issued November, 1991.
n26:hasConcept
n27:M0474041
foaf:page
n16:desmopressin.html n17:desmoprt.htm
n3:IUPAC-Name
n5:271B4101-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4107-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4106-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4103-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4104-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4105-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B40FF-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B40FD-363D-11E5-9242-09173F13E4C5 n5:271B4100-363D-11E5-9242-09173F13E4C5 n5:271B4117-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B40FE-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n24:H01BA02
n3:H-Bond-Acceptor-Count
n5:271B410D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B410E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4108-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4109-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B410B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B410A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B410C-363D-11E5-9242-09173F13E4C5
n3:absorption
Minimally absorbed from the GI tract (average absolute bioavailability = 0.08-0.16%). 10-20% absorbed from nasal mucosa.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
16679-58-6
n3:category
n3:containedIn
n14:271B40E9-363D-11E5-9242-09173F13E4C5 n14:271B40EA-363D-11E5-9242-09173F13E4C5 n14:271B40ED-363D-11E5-9242-09173F13E4C5 n14:271B40EE-363D-11E5-9242-09173F13E4C5 n14:271B40EB-363D-11E5-9242-09173F13E4C5 n14:271B40EC-363D-11E5-9242-09173F13E4C5 n14:271B40F1-363D-11E5-9242-09173F13E4C5 n14:271B40EF-363D-11E5-9242-09173F13E4C5 n14:271B40F0-363D-11E5-9242-09173F13E4C5 n14:271B40DF-363D-11E5-9242-09173F13E4C5 n14:271B40E0-363D-11E5-9242-09173F13E4C5 n14:271B40DD-363D-11E5-9242-09173F13E4C5 n14:271B40DE-363D-11E5-9242-09173F13E4C5 n14:271B40E3-363D-11E5-9242-09173F13E4C5 n14:271B40E4-363D-11E5-9242-09173F13E4C5 n14:271B40E1-363D-11E5-9242-09173F13E4C5 n14:271B40E2-363D-11E5-9242-09173F13E4C5 n14:271B40E7-363D-11E5-9242-09173F13E4C5 n14:271B40E8-363D-11E5-9242-09173F13E4C5 n14:271B40E5-363D-11E5-9242-09173F13E4C5 n14:271B40DB-363D-11E5-9242-09173F13E4C5 n14:271B40DC-363D-11E5-9242-09173F13E4C5 n14:271B40E6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4113-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4115-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4116-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4112-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4111-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4114-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4102-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B410F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4110-363D-11E5-9242-09173F13E4C5